DOCSLIB.ORG

Crediblemeds Filtered Qtdrug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Crediblemeds Filtered Qtdrug List CredibleMeds Filtered QTDrug List The last revision date: September, 10th 2020 See Note below for safe use of this Table The drug list below contains drugs from the categories: Known Risk of TdP AND filtered by Keyword --> " " Generic Name Brand Names (Partial List) Drug Class Therapeutic Use Risk Category Route Aclarubicin (Only Aclacin, Aclacinomycine, Anti-cancer Cancer Risk of injection on Non US Aclacinon, Aclaplastin, TdPAnd Avoid Market) Jaclacin in congenital long QT Amiodarone Cordarone, Pacerone, Antiarrhythmic Arrhythmia Risk of oral, injection Nexterone TdPAnd Avoid in congenital long QT Anagrelide Agrylin, Xagrid Phosphodiesterase 3 Thrombocythemia Risk of oral inhibitor TdPAnd Avoid in congenital long QT Arsenic trioxide Trisenox Anti-cancer Cancer (leukemia) Risk of injection TdPAnd Avoid in congenital long QT Astemizole Hismanal Antihistamine Allergic rhinitis Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Azithromycin Zithromax, Zmax Antibiotic Bacterial infection Risk of oral, injection TdPAnd Avoid in congenital long QT Bepridil Vascor Antianginal Angina Pectoris (heart Risk of oral pain) TdPAnd Avoid in congenital long QT Cesium Chloride Energy Catalyst Toxin Alternative therapy Risk of oral, injection cancer TdPAnd Avoid in congenital long QT Chloroquine Aralen Antimalarial Malaria Risk of oral TdPAnd Avoid in congenital long QT Generic Name Brand Names (Partial List) Drug Class Therapeutic Use Risk Category Route Chlorpromazine Thorazine, Largactil, Antipsychotic / Nausea, Schizophrenia, Risk of oral, Megaphen Antiemetic many others TdPAnd Avoid injection, in congenital suppository long QT Chlorprothixene Truxal Antipsychotic Schizophrenia Risk of oral, injection (Only on Non US TdPAnd Avoid Market) in congenital long QT Cilostazol Pletal Phosphodiesterase 3 Intermittent claudication Risk of oral inhibitor TdPAnd Avoid in congenital long QT Ciprofloxacin Cipro, Cipro-XR, Neofloxin Antibiotic Bacterial infection Risk of oral, injection TdPAnd Avoid in congenital long QT Cisapride Propulsid GI stimulant Increase GI motility Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Citalopram Celexa, Cipramil Antidepressant, SSRI Depression Risk of oral TdPAnd Avoid in congenital long QT Clarithromycin Biaxin, Prevpac Antibiotic Bacterial infection Risk of oral, inhaled TdPAnd Avoid in congenital long QT Cocaine Cocaine Local anesthetic Anesthesia (topical) Risk of oral, nasal TdPAnd Avoid in congenital long QT Disopyramide Norpace Antiarrhythmic Arrhythmia Risk of oral, injection TdPAnd Avoid in congenital long QT Dofetilide Tikosyn Antiarrhythmic Arrhythmia Risk of oral TdPAnd Avoid in congenital long QT Domperidone Motilium, Motillium, Motinorm Antiemetic Nausea, vomiting Risk of oral, (Only on Non US Costi, Nomit TdPAnd Avoid injection, Market) in congenital suppository long QT Donepezil Aricept Cholinesterase Dementia (Alzheimer's Risk of oral inhibitor Disease) TdPAnd Avoid in congenital long QT Generic Name Brand Names (Partial List) Drug Class Therapeutic Use Risk Category Route Dronedarone Multaq Antiarrhythmic Arrhythmia Risk of oral TdPAnd Avoid in congenital long QT Droperidol Inapsine, Droleptan, Dridol, Antipsychotic / Anesthesia (adjunct), Risk of injection Xomolix Antiemetic nausea TdPAnd Avoid in congenital long QT Erythromycin E.E.S., Robimycin, EMycin, Antibiotic Bacterial infection, Risk of oral, injection Erymax, Ery-Tab, Eryc increase GI motility TdPAnd Avoid Ranbaxy, Erypar, Eryped, in congenital Erythrocin Stearate Filmtab, long QT Erythrocot, E-Base, Erythroped, Ilosone, MY-E, Pediamycin, Abboticin, Abboticin-ES, Erycin, PCE Dispertab, Stiemycine, Acnasol, Tiloryth Escitalopram Cipralex, Lexapro, Nexito, Antidepressant, SSRI Depression (major), Risk of oral Anxiset-E, Exodus, Esto, anxiety disorders TdPAnd Avoid Seroplex, Elicea, Lexamil, in congenital Lexam, Entact, Losita, long QT Reposil, Animaxen, Esitalo, Lexamil Flecainide Tambocor, Almarytm, Antiarrhythmic Arrhythmia Risk of oral Apocard, Ecrinal, Flécaine TdPAnd Avoid in congenital long QT Fluconazole Diflucan, Trican Antifungal Fungal infection Risk of oral, injection TdPAnd Avoid in congenital long QT Gatifloxacin Tequin Antibiotic Bacterial infection Risk of oral, injection (Removed from TdPAnd Avoid US Market) in congenital long QT Grepafloxacin Raxar Antibiotic Bacterial infection Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Halofantrine Halfan Antimalarial Malaria Risk of oral (Only on Non US TdPAnd Avoid Market) in congenital long QT Haloperidol Haldol, Aloperidin, Antipsychotic Schizophrenia, agitation Risk of oral, injection Bioperidolo, Brotopon, Dozic, TdPAnd Avoid Duraperidol, Einalon S, in congenital Eukystol, Halosten, Keselan, long QT Linton, Peluces, Serenace, Serenase, Sigaperidol Generic Name Brand Names (Partial List) Drug Class Therapeutic Use Risk Category Route Hydroquinidine Serecor Antiarrhythmic Arrhythmia Risk of oral (Dihydroquinidine) TdPAnd Avoid (Only on Non US in congenital Market) long QT Hydroxychloroqui Plaquenil, Quineprox Antimalarial, Malaria, SLE, Risk of oral ne Anti-inflammatory rheumatoid arthritis TdPAnd Avoid in congenital long QT Ibogaine (Only on Psychedelic Narcotic addiction, Risk of oral Non US Market) unproven TdPAnd Avoid in congenital long QT Ibutilide Corvert Antiarrhythmic Arrhythmia Risk of injection TdPAnd Avoid in congenital long QT Levofloxacin Levaquin, Tavanic Antibiotic Bacterial infection Risk of oral, injection TdPAnd Avoid in congenital long QT Levomepromazin Nosinan, Nozinan, Levoprome Antipsychotic Schizophrenia Risk of oral, injection e TdPAnd Avoid (Methotrimeprazin in congenital e) (Only on Non long QT US Market) Levomethadyl Orlaam Opioid agonist Narcotic dependence Risk of oral acetate (Removed TdPAnd Avoid from US Market) in congenital long QT Levosulpiride Lesuride, Levazeo, Enliva Antipsychotic Schizophrenia Risk of oral, injection (Only on Non US TdPAnd Avoid Market) in congenital long QT Meglumine Glucatime Antiparasitic Leishmaniasis Risk of injection antimoniate (only TdPAnd Avoid on Non US in congenital Market) long QT Mesoridazine Serentil Antipsychotic Schizophrenia Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Methadone Dolophine, Symoron, Opioid agonist Narcotic dependence, Risk of oral, injection Amidone, Methadose, pain TdPAnd Avoid Physeptone, Heptadon in congenital long QT Moxifloxacin Avelox, Avalox, Avelon Antibiotic Bacterial infection Risk of oral, injection TdPAnd Avoid in congenital long QT Nifekalant (Only Shinbit Antiarrhythmic Arrhythmia Risk of injection on Non US TdPAnd Avoid Market) in congenital long QT Generic Name Brand Names (Partial List) Drug Class Therapeutic Use Risk Category Route Ondansetron Zofran, Anset, Ondemet, Antiemetic Nausea, vomiting Risk of oral, Zuplenz, Emetron, Ondavell, TdPAnd Avoid injection, Emeset, Ondisolv, Setronax in congenital suppository long QT Oxaliplatin Eloxatin Anti-cancer Cancer Risk of injection TdPAnd Avoid in congenital long QT Papaverine HCl Vasodilator, Coronary Diagnostic adjunct Risk of injection (Intra-coronary) TdPAnd Avoid in congenital long QT Pentamidine Pentam Antifungal Fungal infection Risk of injection, (Pneumocystis TdPAnd Avoid inhaled pneumonia) in congenital long QT Pimozide Orap Antipsychotic Tourette's Disorder Risk of oral TdPAnd Avoid in congenital long QT Probucol Lorelco Antilipemic Hypercholesterolemia Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Procainamide Pronestyl, Procan Antiarrhythmic Arrhythmia Risk of injection TdPAnd Avoid in congenital long QT Propofol Diprivan, Propoven Anesthetic, general Anesthesia Risk of injection TdPAnd Avoid in congenital long QT Quinidine Quinaglute, Duraquin, Antiarrhythmic Arrhythmia Risk of oral, injection Quinact, Quinidex, Cin-Quin, TdPAnd Avoid Quinora in congenital long QT Roxithromycin Rulide, Xthrocin, Roxl-150, Antibiotic Bacterial infection Risk of oral (Only on Non US Roxo, Surlid, Rulide, Biaxsig, TdPAnd Avoid Market) Roxar, Roximycinv, in congenital Roxomycin, Rulid, Tirabicin, long QT Coroxin Sevoflurane Ultane, Sojourn Anesthetic, general Anesthesia Risk of inhaled TdPAnd Avoid in congenital long QT Sotalol Betapace, Sotalex, Sotacor Antiarrhythmic Arrhythmia Risk of oral TdPAnd Avoid in congenital long QT Generic Name Brand Names (Partial List) Drug Class Therapeutic Use Risk Category Route Sparfloxacin Zagam Antibiotic Bacterial infection Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Sulpiride (Only Dogmatil, Dolmatil, Eglonyl, Antipsychotic, Schizophrenia Risk of oral, inhaled on Non US Espiride, Modal, Sulpor atypical TdPAnd Avoid Market) in congenital long QT Sultopride (Only Barnetil, Barnotil, Topral Antipsychotic, Schizophrenia Risk of oral, injection on Non US atypical TdPAnd Avoid Market) in congenital long QT Terfenadine Seldane Antihistamine Allergic rhinitis Risk of oral (Removed from TdPAnd Avoid US Market) in congenital long QT Terlipressin (Only Teripress, Glypressin, Vasoconstrictor Septic shock Risk of injection on Non US Terlipin, Remestyp, Tresil, TdPAnd Avoid Market) Teriss in congenital long QT Terodiline (Only Micturin, Mictrol Muscle relaxant Bladder spasm Risk of oral on Non US TdPAnd Avoid Market) in congenital long QT Thioridazine Mellaril, Novoridazine, Thioril Antipsychotic Schizophrenia Risk of oral TdPAnd Avoid in congenital long QT Vandetanib Caprelsa Anti-cancer Cancer (thyroid) Risk of oral TdPAnd Avoid in congenital long QT
Load more

Recommended publications
  • Veterinary Emergency & Anaesthesia Pfizer
    AVA ECVA & AVEF Thank all their sponsors for this spring edition PARIS 2007 On VETERINARY EMERGENCY & ANAESTHESIA PFIZER MERIAL FORT DODGE BAYER BOEHRINGER MEDISUR COVETO OPTOMED HALLOWELL SCIL JANSSEN SOGEVAL KRUSSE TECHNIBELT MILA TEM The Organisatiors 7th AVEF European Meeting- 10th March 2007-ROISSY 2 AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France AVA PARIS 2007 — Wednesday March 7th RESIDENT DAY RUMINANT ANAESTHESIA Hyatt Regency Hotel, Roissy CDG, France K OTTO, D HOLOPHERNE, G TOUZOT 8.30 REGISTRATIONS 9.00-9.45 Specific anatomo-physiology to consider for ruminant peri-anaesthetic period K OTTO 10.00-10.30 COFFEE BREAK 10.30-11.15 Post-anaesthetic and pain management in ruminants K OTTO 11.30-12.15 Physical restraint and sedation of ruminants D HOLOPHERNE 12.30-1.30 LUNCH 1.30-2.15 Anaesthesia of Lamas & Alpagas G TOUZOT 2.30-3.15 Regional & local anaesthesia for ruminants D HOLOPHERNE 3.30-4.00 COFFEE BREAK 4.00-4.45 Pharmacology and protocols for ruminant anaesthesia G TOUZOT AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France Specific anatomo-physiology to consider for ruminants peri-anaesthetic period Klaus A. Otto Institut für Versuchstierkunde und Zentrales Tierlaboratorium, Medizinische Hochschule Hannover, D-30623 Hannover, Germany The suborder “ruminantia” includes members of the family “bovidae” such as cattle (bos taurus), sheep (ovis spp) and goats (capra spp). Members of the family “camelidae” (camelus spp, llama spp, vicugna spp) belong to the suborder “tylopodia” and therefore are not true ruminants.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,844,355 B2 Somberg Et Al
    USOO684.4355B2 (12) United States Patent (10) Patent No.: US 6,844,355 B2 Somberg et al. (45) Date of Patent: Jan. 18, 2005 (54) OPTICALLY ACTIVE ISOMERS OF QUININE Catterall, (1992) Physiol. Rev. 72(supp):S15-S48. AND QUINDINE AND THEIR RESPECTIVE Chan et al., (1991) J. Chromatogr. 571:291-297. BIOLOGICALACTION Chen et al., (1998) Nature 392:293–296. (75) Inventors: John C. Somberg, Lake Forest, IL Coplen et al., (1991) Circulation 84:527. (US); Vasant Ranade, Libertyville, IL Drabowicz et al., (1984) “Chemical Abstracts” Phosphorus (US) Sulfur 16:2676–270 (XP002165239). Engler et al., (1985) Helv. Chim. Acta. 68:789–800. (73) Assignee: Academic Pharmaceuticals, Inc., Lake Ficker et al., (1998) Circ. Res. 82:386–395. Bluff, IL (US) Gellens et al., (1992) Proc. Natl. Acad. Sci. 89:554–558. (*) Notice: Subject to any disclaimer, the term of this Gutzwiller et al., (1973) “Chemical Abstracts” Helv. Chim. patent is extended or adjusted under 35 Acta. 79:1494–1503 (XP002165238). U.S.C. 154(b) by 0 days. Hartmann et al. (1994) Circ. Res. 75:114-122. Karle I.L. et al., (1981) Proc. Natl. Acad. Sci. 78:5938–5941. (21) Appl. No.: 10/168,919 Karle, J.M. (1997) Antimicrob. Agents Chemother. (22) PCT Filed: Dec. 22, 2000 41:791-794. Kiehn et al. (1996) Circulation 94:2572–2579. (86) PCT No.: PCT/US00/352.13 Krafte et al., (1994) Europ. J. Pharma. 266:245-254. S371 (c)(1), Li et al. (1996) Circ. Res. 78:689-696. (2), (4) Date: Oct. 30, 2002 Sanguinetti et al., (1990) J.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • 021879Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 021879Orig1s000 OTHER REVIEW(S) 505(b)(2) ASSESSMENT Application Information NDA # 021879 NDA Supplement #: S- N/A Efficacy Supplement Type SE- N/A Proprietary Name: Nuedexta Established/Proper Name: (dextromethorphan/quinidine) Dosage Form: Capsules Strengths: dextromethorphan 20mg with quinidine 10 mg Applicant: Avanir Pharmaceuticals, Inc. Date of Receipt: April 30, 2010 PDUFA Goal Date: October 30, 2010 Action Goal Date (if different): Proposed Indication(s): indicated for the treatment of pseudobulbar affect (PBA) secondary to either amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS) GENERAL INFORMATION 1) Is this application for a recombinant or biologically-derived product and/or protein or peptide product OR is the applicant relying on a recombinant or biologically-derived product and/or protein or peptide product to support approval of the proposed product? YES NO If “YES “contact the (b)(2) review staff in the Immediate Office, Office of New Drugs. ReferenceVersion ID: 2857112 March 2009 page 1 INFORMATION PROVIDED VIA RELIANCE (LISTED DRUG OR LITERATURE) 2) List the information essential to the approval of the proposed drug that is provided by reliance on our previous finding of safety and efficacy for a listed drug or by reliance on published literature. (If not clearly identified by the applicant, this information can usually be derived from annotated labeling.) Source of information* (e.g., Information provided (e.g., published literature, name of pharmacokinetic data, or specific referenced product) sections of labeling) quinidine sulfate nonclinical safety literature nonclinical safety *each source of information should be listed on separate rows 3) Reliance on information regarding another product (whether a previously approved product or from published literature) must be scientifically appropriate.
    [Show full text]
  • Federal Register/Vol. 71, No. 34/Tuesday, February 21, 2006
    Federal Register / Vol. 71, No. 34 / Tuesday, February 21, 2006 / Notices 8859 DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND of the Public Health Service Act to HUMAN SERVICES HUMAN SERVICES conduct directly or by grants or contracts, research, experiments, and Office of the National Coordinator; Office of the National Coordinator; demonstrations relating to occupational American Health Information American Health Information safety and health and to mine health. Community Chronic Care Workgroup Community Consumer Empowerment The BSC shall provide guidance to the Meeting Workgroup Meeting Director, NIOSH on research and prevention programs. Specifically, the ACTION: Announcement of meeting. ACTION: Announcement of meeting. board shall provide guidance on the institute’s research activities related to SUMMARY: SUMMARY: This notice announces the This notice announces the developing and evaluating hypotheses, third meeting of the American Health third meeting of the American Health Information Community Consumer systematically documenting findings Information Community Chronic Care and disseminating results. The board Workgroup in accordance with the Empowerment Workgroup in accordance with the Federal Advisory shall evaluate the degree to which the Federal Advisory Committee Act (Pub. activities of NIOSH: (1) Conform to L. 92–463, 5 U.S.C., App.) Committee Act (Pub. L. 92–463, 5 U.S.C., App.) appropriate scientific standards, (2) DATES: March 22, 2006 from 1 p.m. to address current, relevant needs, and (3) DATES: March 20, 2006 from 1 p.m. to 5 p.m. produce intended results. 5 p.m. ADDRESSES: Hubert H. Humphrey Matters to be Discussed: Agenda items ADDRESSES: Hubert H. Humphrey Building (200 Independence Ave., SW., include a report from the Director, Building (200 Independence Ave., SW., Washington, DC 20201), Conference NIOSH; progress report by BSC working Washington, DC 20201), Conference Room 705A.
    [Show full text]
  • Anesthetics; Drugs of Abuse & Withdrawal
    Anesthetics; Drugs of Abuse & Withdrawal Kurt Kleinschmidt, MD, FACEP, FACMT Professor of Emergency Medicine Section Chief and Program Director Medical Toxicology UT Southwestern Medical Center Much Thanks To… Sean M. Bryant, MD Associate Professor Cook County Hospital (Stroger) Department of Emergency Medicine Assistant Fellowship Director: Toxikon Consortium Associate Medical Director Illinois Poison Center Overview Anesthetics – Local – Inhalational – NM Blockers & Malignant Hyperthermia Drugs of Abuse (Pearls) Withdrawal History 1904-Procaine (short Duration of Action) 1925 (dibucaine) & 1928 (tetracaine) → potent, long acting 1943-lidocaine 1956-mepivacaine, 1959-prilocaine 1963-bupivacaine, 1971-etidocaine, 1996-ropivacaine Lipophili Intermediate Amine Substituents c Group Esters Structure 2 Distinct Groups 1) Amino Esters Amides 2) Amino Amides Local Anesthetics Toxic Reactions • Few & iatrogenic • Blood vessel administration or toxic dose AMIDES have largely replaced ESTERS • Increased stability • Relative absence of hypersensitivity reactions – ESTER hydrolysis = PABA (cross sensitivity) – AMIDES = Multidose preps → methylparabens • Chemically related to PABA with rare allergic reactions Local Anesthetics Mode of Action • Reversible & Predictable Binding • Within membrane-bound sodium channels of conducting tissue (cytoplasmic side of membrane) → Failure to form/propagate action potentials (Small-diam. fibersBLOCKADE carrying pain/temp sensation) Pain fibers - higher firing rate & longer AP → • ↑Sodium susceptible Channelto local
    [Show full text]
  • Potentially Harmful Drugs for Mitochondrial Patients September 2016, Version 3
    POTENTIALLY HARMFUL DRUGS FOR MITOCHONDRIAL PATIENTS SEPTEMBER 2016, VERSION 3 When the diagnosis of a mitochondrial disease is made, you (as a patient) may be confronted with medication/drugs to be used. Up to now there is no treatment for mitochondrial disorders. There are no therapies which can solve the primary problem: the lack of energy. However, it is possible to deal with specific complaints with so called symptomatic treatments. For example: a mitochondrial disorder can lead to epileptic seizures, which can be treated with anti-epileptics or in case of cardiomyopathy (when the heart muscle is affected) specific heart medication can be given. Additionally, you can be confronted with medication when you have to undergo surgery or medical investigation and need anaesthesia. It is of the utmost importance to realise that certain drugs may be potentially harmful for patients with mitochondrial disorders. The cause of the possible larger risk of unwanted negative effects of certain drugs with mitochondrial disorders in general lies in the fact that the drugs have a negative impact on the mitochondrial function. The (group of) drugs of which it is scientifically known that there is an (possible) increased risk on harmful effects with mitochondrial patients are listed in the table below. The kind of scientific evidence for negative effects on the mitochondrial function differs per (group of) drugs. We labelled the (group of) drugs based on the kind of scientific evidence, while we do not aim to restrict important drugs in a condition where treatment options are already so limited. In the majority it concerns experimental data, marked as yellow.
    [Show full text]
  • Supplemental Anesthesia & Analgesia Information This Supplemental
    Supplemental Anesthesia & Analgesia Information This supplemental information was prepared by members of the Veterinary Task Force to Advance Spay-Neuter (VTFASN) as a companion piece to the Association of Shelter Veterinarian’s Veterinary Medical Care Guidelines for Spay-Neuter Programs (Guidelines). Anesthesia and Analgesia Guidelines for High Quality, High Volume Spay/Neuter Initiatives Andrea L. Looney, DVM, DACVA, Leslie D. Appel, DVM, Mark W. Bohling, DVM, PhD, DACVS, Y. Karla Rigdon-Brestle, DVM, Philip A. Bushby, DVM, MS, DACVS, Nancy J. Ferguson, DVM, Brenda Griffin, DVM, MS, DACVIM, David J. Sweeney, DVM, Kathy A. Tyson, DVM, Adriana H. Voors, DVM, Sara C. White, DVM; Edited by Joan E. Dempsey, MFA INTRODUCTION As a recent ad campaign for inhalant anesthesia stated, “There’s a lot more to good anesthesia than simply life and death or waking from the event (1).” In other words, the fact that an animal makes it through surgery is no longer a good criterion by which to measure adequacy in our choices of anesthetic drugs, monitoring or stabilization. We understand now that what we have done or failed to do pre-, intra- or postoperatively has sometimes caused animals to succumb to perioperative disease within weeks or months of the surgery. Our historical presumptions of successful anesthesia, indicated by animals that appear stable under anesthesia or wake up quickly or well, are no longer adequate. Why is this so? The answer is relatively simple. Despite all our advancements within the fields of both human and veterinary anesthesiology, and regardless of whether we use simple mask inhalants or potent premeds such as Xylazine, anesthesia remains a profound cardiorespiratory depressant event which is capable of causing disease and death.
    [Show full text]
  • Substitution of Isoflurane by Sevoflurane Toward the End of Long Surgeries Is Cost Effective
    Alexandria Journal of Anaesthesia and Intensive Care 24 Substitution of Isoflurane by Sevoflurane Toward the End of Long Surgeries Is Cost Effective Moatz El-Tawil, Mohamed Yasser El Bahar Faculty of Medicine - Menofiya University ABSTRACT The lower solubility of sevoflurane allows a more rapid emergence from anesthesia than after anesthesia with more soluble but less expensive anesthetic isoflurane. Cost control in anesthesia is no longer an option; it is a necessity. We substitute sevoflurane for isoflurane toward the end of anesthesia for operations longer than 3 hours in an attempt to combine the cost effectiveness of isoflurane with rapid emergence from sevoflurane. Sixty patients undergoing long abdominoplastic and ENT surgeries were randomly equally divided into three groups: group I (isoflurane group), group II (crossover group) where isoflurane was substituted by sevoflurane during the last 30 minutes of the operation and group III (sevoflurane group). A fresh gas flow of 2 L/min as 60% N2O in O2 was used for maintenance of anesthesia. Consumption of volatile anesthetics was measured by weighing the vaporizers with a precision weighing machine and recovery variables were recorded. The times for spontaneous breathing, times to opening eyes, squeeze a finger on command, times for extubation, orientation, times to read Aldrete score > 9 and time to discharge from PACU, all these times were significantly longer in isoflurane group than the crossover and sevoflurane groups and no significant difference between crossover and isoflurane groups. Cost was significantly higher in sevoflurane group (1.242 EP per minute anesthesia). The costs among the other two groups did not differ significantly (0.319 EP/min for isoflurane group and 0.344 EP/min for crossover group).
    [Show full text]
  • 1 Comparison of the Effects of Buprenorphine and Methadone in 1
    1 Comparison of the effects of buprenorphine and methadone in 2 combination with medetomidine followed by intramuscular alfaxalone for 3 anaesthesia of cats undergoing ovariohysterectomy. 4 5 Corresponding author: Kate L White, MA VetMB, DVA, Dipl ECVAA, MRCVS, 6 School of Veterinary Medicine and Science, University of Nottingham, 7 Loughborough, LE12 5RD, UK 8 e-mail: [email protected] 9 Tel: +44 (0)1159516096 10 11 12 Authors: 13 Mahdmina A, RSPCA Greater Manchester Animal Hospital, 411 Eccles New 14 Rd, Salford, M5 5NN 15 16 Evans, A, Rutland House Veterinary Hospital, 4 Abbotsfield Road, St. Helens, 17 WA9 4HU 18 19 Yates D, RSPCA Greater Manchester Animal Hospital, 411 Eccles New Rd, 20 Salford, M5 5NN 1 21 22 White KL, School of Veterinary Medicine and Science, University of Nottingham, 23 Loughborough, LE12 5RD, UK 24 25 Abstract 26 Objectives: The aim of this study was to compare quality of anaesthesia and 27 analgesia between methadone and buprenorphine in combination with 28 medetomidine after induction with intra-muscular (IM) alfaxalone in cats 29 undergoing ovariohysterectomy. 30 Methods: Fifty-one female cats (ASA I - II), median age 12 months (range 2 – 60), 31 weighing 2.5 ± 0.5 kg were recruited to the study. Cats were randomly allocated 32 to receive medetomidine (600 µg/m2) and buprenorphine (180 µg/m2) (group 33 MB) or medetomidine (500 µg/m2) and methadone (5 mg/m2) (group MM) IM. 34 Anaesthesia was induced 15 minutes later using alfaxalone (3 mg/kg) IM. 35 Anaesthesia was maintained with isoflurane in oxygen. All cats received 36 meloxicam pre-operatively.
    [Show full text]
  • Comparison of Sevoflurane and Halothane Masaki Yurino MD Phl), Hitomi Kirnura MD
    440 Vital capacity rapid inhalation induction technique: comparison of sevoflurane and halothane Masaki Yurino MD Phl), Hitomi Kirnura MD Induction of anaesthesia using the vital capacity rapid inhal- de cette dpreuve et chacun d'eux a refu un des deux agents: ation induction (VCRI1) technique with either sevoflurane or 17 ont refu le sdvoflurane et 15, l~alothane. Non pr~m~diquds, halothane was compared. The induction time, characteristics, ils ont inspir~ approximativement 2,6 fois l~quivalent de la and acceptability were assessed. Thirty-two volunteers were concentration alvdolaire minimum (CAM) de l'un ou de l'autre given one of the vapours: 17 received sevoflurane and 15 halo- des agents. II n'y avait de differences entre les parambtres cardio- thane. Subjects were unpremedicated and breathed approxi- vasculaires et respiratoires. La dur~e moyenne de l'induction mately 2.6 • minimum alveolar concentration (MAC) equiv- de l'anesth~sie avec l'halothane (153 + 46 sec, SD) a dtd plus alent of either agent. There were no differences in the patients' lente que celle produite par le s~voflurane (81 + 22 sec, SD, cardiovascular or respiratory variables. The mean time for in- P < 0,05), ce qui reflbte son coefficient de solubilit$ sang:gaz duction of anaesthesia with halothane (153 + 46 sec, SD) was plus dlev~. L~ncidence des complications telles que la toux et slower than with sevoflurane (81 + 22 sec, SD, P < 0.05), les mouvements a dt~ moindre avec s$voflurane qu'avec l~a- reflecting its higher blood:gas solubility. There were fewer in- lothane.
    [Show full text]